GlassScriptPhysician profile
Candice Renee Lovelace
NPI 1215248307
$7,980.71
in general payments reported to CMS, 2019-2025
41 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $385 · 2021: $419 · 2022: $1,454 · 2023: $1,523 · 2024: $1,538 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,485 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,484.85 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,463.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,142.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $955.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $828.33 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $531.03 | 2021-2025 | |
| Pfizer INC. | $413.63 | 2019-2025 | |
| Amgen INC. | $373.18 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.59 | 2019-2025 | Jardiance, Stiolto Respimat |
| Abbott Laboratories | $244.43 | 2019-2025 | Freestyle Libre 3 |
| Intuitive Surgical, INC. | $191.18 | 2020 | |
| Phathom Pharmaceuticals, INC. | $182.79 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $164.87 | 2022-2024 | Heplisav-B |
| Abiomed | $122.42 | 2025 | |
| Biodelivery Sciences International, INC. | $114.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.48 | 2020-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candice Lovelace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.